Low high-density lipoprotein cholesterol (HDL-C) increases cardiovascular risk, whereas its high levels protect against atherosclerosis via multiple beneficial effects. Dense and poorly lysable fibrin clot formation is observed in cardiovascular disease. We sought to investigate whether HDL-C and its major component apolipoprotein A (Apo A)-I affect fibrin clot properties. In 136 apparently healthy individuals (99 men, 37 women, aged 49–69 years) we determined plasma fibrin clot permeability (Ks coefficient) and lysis time (t50%) together with Apo A-I and lipoprotein (a) [Lp(a)] levels. The median HDL-C level was 1.33 mmol/l (range from 0.77 to 2.19 mmol/l). HDL-C was positively associated with Apo A-I (r = 0.62, P < 0.00001). HDL-C and Apo A-I were positively correlated with Ks (r = 0.52, P < 0.00001 and r = 0.44, P < 0.00001, respectively) and inversely with t50% (r = −0.44, P < 0.00001 and r = −0.35, P = 0.00003, respectively). No such associations were seen for other lipid variables. Ks and t50% were associated with Lp(a) (r = −0.42, P < 0.00001 and r = 0.42, P < 0.00001, respectively) and fibrinogen (r = −0.31, P = 0.00024 and r = 0.39, P < 0.00001, respectively). Individuals with HDL-C at least 1.4 mmol/l (n = 54) had 19% higher Ks (P = 0.00016) and 17% shorter t50% (P = 0.0012) than the remainder. After adjustment for age, fibrinogen, and Lp(a), HDL-C was the independent predictor of Ks (β = 0.7, P < 0.00001) and t50% (β = −0.62, P < 0.00001). This study shows that elevated HDL-C levels are associated with improved fibrin clot permeability and lysis, indicating a novel antithrombotic mechanism underlying the postulated beneficial effects of therapy targeted at HDL-C.
Mammalian flavin-containing monooxygenases are difficult to obtain and study while they play a major role in detoxifying various xenobiotics. In order to provide alternative biocatalytic tools to generate FMO-derived drug metabolites, a collection of microbial flavoprotein monooxygenases, sequence-related to human flavin-containing monooxygenases (FMOs), was tested for their ability to oxidize a set of xenobiotic compounds. For all tested xenobiotics (nicotine, lidocaine, 3-(methylthio)aniline, albendazole, and fenbendazole), one or more monooxygenases were identified capable of converting the target compound. Chiral LC-MS/MS analyses of the conversions of 3-(methylthio)aniline, albendazole and fenbendazole revealed that the respective sulfoxides are formed in good to excellent enantiomeric excess by several of the tested monooxygenases. Intriguingly, depending on the chosen microbial monooxygenase, either the (R)- or (S)-sulfoxide was formed. For example, when using a monooxygenase from Rhodococcus jostii the (S)-sulfoxide of albendazole (ricobendazole) was obtained with an e.e. of 95%, while a fungal monooxygenase yielded the respective (R)-sulfoxide in 57% e.e. For nicotine and lidocaine, monooxygenases could be identified that convert the amines into their respective N-oxides. This study shows that recombinantly expressed microbial monooxygenases represent a valuable toolbox of mammalian FMO mimics that can be exploited for the production of FMO-associated xenobiotic metabolites.
Manipulation of high-density materials, such as crystals and liquid condensates, is of great importance for many applications, including serial crystallography, structural and molecular biology, chemistry, and medicine. In this work, we describe an acoustic technique to focus and harvest flowing crystals and liquid condensates. Moreover, we show, based on numerical simulations, that the acoustic waves can be used for size-based particle (crystals, droplets, etc.) separation. This is an essential technological step in biological research, medical applications, and industrial processes. The presented technology offers high precision, biocompatibility, ease of use and additionally, is non-invasive and inexpensive. With the recent advent of X-ray Free Electron Laser (XFEL) technology and the associated enormous importance of a thin jet of crystals, this technology might pave the way to a novel type of XFEL injector.